Quantitative podocyte parameters predict human native kidney and allograft half-lives

JCI Insight

Volumn 1, Issue 7, 2016, Pages

  Naik, Abhijit S ^a   Afshinnia, Farsad ^a   Cibrik, Diane ^a   Hodgin, Jeffrey B ^a   Wu, Fan ^b   Zhang, Min ^b   Kikuchi, Masao ^a   Wickman, Larysa ^c   Samaniego, Milagros ^a   Bitzer, Markus ^a   Wiggins, Jocelyn E ^a   Ojo, Akinlolu ^a   Li, Yi ^b   Wiggins, Roger C ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84984673660     PISSN: None     EISSN: 23793708     Source Type: Journal    
DOI: 10.1172/jci.insight.86943     Document Type: Article

References (47)

1. Kriz W, Gretz N, Lemley KV. Progression of glomerular diseases: Is the podocyte the culprit? Kidney Int. 1998;54(3):687-697.
2. Kriz W, LeHir M. Pathways to nephron loss starting from glomerular diseases: insights from animal models. Kidney Int. 2005;67:404-419.
3. Wiggins RC. The spectrum of podocytopathies: a unifying view of glomerular diseases. Kidney Int. 2007;71(12):1205-1214.
4. Kikuchi M, Wickman L, Wiggins RC. Podometrics as a potential clinical tool for glomerular disease management. Semin Nephrol. 2015;35(3):245-255.
5. Wharram BL, et al. Podocyte depletion causes glomerulosclerosis: Diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene. J Am Soc Nephrol. 2005;16(10):2941-2952.
6. Fukuda A, et al. Angiotensin II-dependent persistent podocyte loss from destabilized glomeruli causes progression of end stage kidney disease. Kidney Int. 2012;81(1):40-55.
7. Fukuda A, et al. Growth-dependent podocyte failure causes glomerulosclerosis. J Am Soc Nephrol. 2012;23(8):1351-1363.
8. Brown EJ, Pollak MR, Barua M. Genetic testing for nephrotic syndrome and FSGS in the era of next-generation sequencing. Kidney Int. 2014;85(5):1030-1038.
9. Sadowski CE, et al. A single-gene cause in 29.5% of cases of steroid-resistant nephrotic syndrome. J Am Soc Nephrol. 2015;26(6):1279-1289.
10. Pagtalunan ME, et al. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest. 1997;99(2):342-348.
11. Meyer TW, Bennett PH, Nelson RG. Podocyte number predicts long-term urinary albumin excretion in Pima Indians with type II diabetes and microalbuminuria. Diabetologia. 1999;42(11):1341-1344.
12. Steffes MW, Schmidt D, McCrery R, Basgen JM. International Diabetic Nephropathy Study Group: glomerular cell number in normal subjects and type I diabetes patients. Kidney Int. 2001;59(6):2104-2113.
13. White KE, et al. European Study for the Prevention of Renal Disease in Type I Diabetes (ESPRIT): podocyte number in normotensive type I diabetic patients with albuminuria. Diabetes. 2002;51(ESPRIT):3083-3089.
14. Lemley KV, et al. Podocytopenia and disease severity in IgA nephropathy. Kidney Int. 2002;61(4):1475-1485.
15. Della Vestra M, Masiero A, Roiter AM, Saller A, Crepaldi G, Fioretto P. Is podocyte injury relevant in diabetic nephropathy? Studies in patients with type 2 diabetes. Diabetes. 2003;52(4):1031-1035.
16. Wang G, et al. Podocyte loss in human hypertensive nephrosclerosis. Am J Hypertens. 2009;22(3):300-306.
17. Hodgin J, et al. Kidney aging and focal global glomerulosclerosis. a podometric perspective. J Am Soc Nephrol. 2015;26(12):3162-3178.
18. Wickman L, et al. Urine podocyte mRNAs, proteinuria, and progression in human glomerular diseases. J Am Soc Nephrol. 2013;24(12):2081-2095.
19. Yang Y, et al. The two kidney to one kidney transition and transplant glomerulopathy: A podocyte perspective. J Am Soc Nephrol. 2015;26(6):1450-1465.
20. Meier-Kriesche HU, et al. Interaction between donor and recipient age in determining the risk of chronic renal allograft failure. J Am Geriatr Soc. 2002;50(1):14-17.
21. Kaplan C, Pasternack B, Shah H, Gallo G. Age-related incidence of sclerotic glomeruli in human kidneys. Am J Pathol. 1975;80(2):227-234.
22. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey Data: NANES 2009-2010. http://wwwn.cdc.gov/Nchs/Nhanes/Search/nhanes09_10.aspx, Accessed May 7, 2016.
23. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey Data: NANES 2011-2012. http://wwwn.cdc.gov/Nchs/Nhanes/Search/nhanes11_12.aspx, Accessed May 7, 2016.
24. United States Renal Data System. 2012 Annual Data Report. USRDS Web site. http://www.usrds.org/atlas12.aspx. Accessed April 25, 2016.
25. [No authors listed]. Special issue: OPTN/SRTR Annual Data Report 2014. Am J Transplant. 2016;16(S2):4-215.
26. Weissgerber TL, Craici IM, Wagner SJ, Grande JP, Garovic VD. Advances in the pathophysiology of preeclampsia and related podocyte injury. Kidney Int. 2014;86(2):275-285.
27. White WM, et al. Persistent urinary podocyte loss following preeclampsia may reflect subclinical renal injury. PLoS One. 2014;9(3):e92693.
28. Kandasamy Y, Watson D, Rudd D. Biomarker of early glomerular injury in pre-eclampsia. Hypertens Pregnancy. 2015;34(4):391-399.
29. Henao DE, Saleem MA. Proteinuria in preeclampsia from a podocyte injury perspective. Curr Hypertens Rep. 2013;15(6):600-605.
30. Lopez-Otin C, Blasco M, Partridge A, Serrano M, Kroermer G. The hallmarks of aging. Cell. 2013;153(6):1194-1217.
31. Wiggins J, et al. Podocyte hypertrophy, "adaptation" and "decompensation" associated with glomerular enlargement and glomerulosclerosis in the aging rat: prevention by calorie restriction. J Am Soc Nephrol. 2005;16(10):2953-2966.
32. Lamb K, Lodhi S, Meier-Kriesche HU. Long term renal allograft survival in the United States: a critical reappraisal. Am J Transplant. 2011;11(3):450-462.
33. Dharnidharka VR, Lamb KE, Zheng J, Schechtman KB, Meier-Kriesche HU. Lack of significant improvements in long-term allograft survival in pediatric solid organ transplantation: a US national registry analysis. Pediatr Transplant. 2015;19(5):477-483.
34. Venner J, Famulski K, Reeve J, Chang J, Halloran P. Relationships among injury, fibrosis, and time in human kidney transplants. JCI Insight. 2016;1(1):e85323.
35. Einecke G, et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant. 2009;9(11):2520-2531.
36. Sellarés J, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant. 2012;12(2):388-399.
37. Loupy A, et al. Molecular microscope strategy to improve risk stratification in early antibody-mediated kidney allograft rejection. J Am Soc Nephrol. 2014;25(10):2267-2277.
38. Amer H, Cosio FG. Significance and management of proteinuria in kidney transplant recipients. J Am Soc Nephrol. 2009;20(12):2490-2492.
39. Serón D, Burgos D, Alonso A. Histology and proteinuria after renal transplantation. Transplant Rev (Orlando). 2012;26(1):20-26.
40. Soler MJ, Riera M, Gutierrez A, Pascual J. New options and perspectives for proteinuria management after kidney transplantation. Transplant Rev (Orlando). 2012;26(1):44-52.
41. Halloran PF, Melk A, Barth C. Rethinking chronic allograft nephropathy: the concept of accelerated senescence. J Am Soc Nephrol. 1999;10(1):167-181.
42. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med. 2003;349(24):2326-2333.
43. El-Zoghby ZM, et al. Identifying specific causes of kidney allograft loss. Am J Transplant. 2009;9(3):527-535.
44. Risdon R, Sloper J, De Wardener H. Relationship between renal function and histological changes found in renal biopsy speci mens from patients with persistent glomerular nephritis. Lancet. 1968;17(7564):363-365.
45. Bohle A, Mackensen-Haen S, von Gise H. Significance of tubulointerstitial changes in the renal cortex for the excretory function and concentration ability of the kidney: a morphometric contribution. Am J Nephrol. 1987;7(6):421-433.
46. Kaissling B, LeHir M, Kriz W. Renal epithelial injury and fibrosis. Biochim Biophys Acta. 2013;1832(7):931-939.
47. Obesity Prevalence Maps. Centers for Disease Control and Prevention Web Site. http://www.cdc.gov/obesity/data/prevalencemaps. html. Updated September 11, 2015. Accessed May 5, 2016.